|
private:inticabiomedical
|
3058630
|
May 29th, 2019 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
May 29th, 2019 01:05AM
|
May 29th, 2019 01:05AM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
Open
|
|
Open
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Mar 19th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Mar 18th, 2018 10:16PM
|
Mar 18th, 2018 10:16PM
|
|
Open
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 17th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 16th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 15th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 14th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 13th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 12th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 11th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|
|
private:inticabiomedical
|
3058630
|
Feb 10th, 2018 12:00AM
|
INTICA Biomedical
|
17
|
1.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
|
|
|
|
|
|
|
|
|
|
INTICA Biomedical
|
|
Pharmaceuticals & Biotechnology
|